ArrePath Raises $20 Million in Seed Round  

by Kay Aloha Villamor in March 4th, 2022

ArrePath, a Princeton, New Jersey-based anti-infective drug discovery company addressing the global health challenge of drug-resistant infections, announced today that it raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives to overcome antimicrobial resistance (AMR). 

The Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures co-led the financing, which also included Viva BioInnovator, Arimed Capital, PTX Capital, and Nor’easter Ventures.

ArrePath also announced that Dr. Lloyd Payne has been named President and CEO.

Company: ArrePath

Raised: $20.0M

Round: Seed Round

Funding Month: March 2022

Lead Investors: Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures

Additional Investors: Viva BioInnovator, Arimed Capital, PTX Capital, and Nor’easter Ventures

Company Website: https://arrepath.com/

Software Category: Machine learning (ML) and imaging-based drug discovery platform

About the Company: ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state-of-the-art technologies and novel strategies. ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug-resistant infections. The company’s proprietary machine learning (ML)-based platform enables the rapid and efficient identification of anti-infective agents with new mechanisms of action at the outset of the discovery process, through a deep understanding and analysis of pathogen behavior. ArrePath’s approach leverages a novel technology platform to enable the discovery and development of new and differentiated antibiotics by decoding the complex behavior of bacteria when exposed to new chemical entities (known as ‘bacterial autopsies’), leading to the efficient elucidation of biological mechanisms of action. The platform’s proof-of-concept has been demonstrated in studies published in Cell by ArrePath’s scientific founder, Zemer Gitai, Ph.D., Edwin Grant Conklin Professor of Biology at Princeton University. 

Source: https://www.businesswire.com/news/home/20220303005116/en/ArrePath-Announces-20-Million-Seed-Financing-to-Advance-its-Machine-Learning-based-Platform-for-Discovery-of-Novel-Anti-infectives-Addressing-Antimicrobial-Resistance




Your cart
    Checkout